Insider Selling: Sight Sciences (NASDAQ:SGHT) Insider Sells 9,385 Shares of Stock

by · The Cerbat Gem

Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) insider Jeremy Hayden sold 9,385 shares of Sight Sciences stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $7.82, for a total transaction of $73,390.70. Following the sale, the insider owned 247,205 shares of the company’s stock, valued at approximately $1,933,143.10. The trade was a 3.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Sight Sciences Stock Performance

Shares of SGHT stock traded down $0.24 during trading hours on Tuesday, hitting $7.47. The company’s stock had a trading volume of 197,717 shares, compared to its average volume of 290,394. The stock has a market cap of $394.94 million, a PE ratio of -8.30 and a beta of 2.42. Sight Sciences, Inc. has a 12-month low of $2.03 and a 12-month high of $9.24. The company has a 50 day moving average of $7.52 and a 200 day moving average of $5.13. The company has a current ratio of 9.60, a quick ratio of 8.93 and a debt-to-equity ratio of 0.62.

Sight Sciences (NASDAQ:SGHT – Get Free Report) last posted its earnings results on Wednesday, September 8th. The company reported ($0.81) earnings per share (EPS) for the quarter. The business had revenue of $12.54 million for the quarter. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. On average, sell-side analysts forecast that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Trading of Sight Sciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Long Focus Capital Management LLC lifted its position in Sight Sciences by 1.3% in the third quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company’s stock valued at $10,985,000 after buying an additional 41,797 shares during the last quarter. Millennium Management LLC raised its stake in shares of Sight Sciences by 145.2% in the 3rd quarter. Millennium Management LLC now owns 133,846 shares of the company’s stock valued at $460,000 after acquiring an additional 79,265 shares during the period. Alliancebernstein L.P. lifted its holdings in shares of Sight Sciences by 5.5% in the 3rd quarter. Alliancebernstein L.P. now owns 34,380 shares of the company’s stock worth $118,000 after acquiring an additional 1,800 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after purchasing an additional 3,785 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in Sight Sciences by 1.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 303,634 shares of the company’s stock valued at $1,045,000 after purchasing an additional 3,051 shares during the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

  • Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight (from Neutral), a buy-side analyst upgrade that can attract investor interest and buying momentum. Piper Sandler upgrade
  • Neutral Sentiment: Despite recent sales, insiders still hold large positions — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) retain substantial ownership, which can indicate alignment with long-term value even as they trim stakes. Insider ownership filing
  • Negative Sentiment: Clustered insider selling by executives — CEO Paul Badawi, CTO David Badawi, CFO James Rodberg, EVP Brenton Taylor and insider Jeremy Hayden — over Jan. 2–6. Combined disclosed sales total roughly $0.48M across these transactions; each sale was a small percentage (CEO sale filing CTO sale filing Other insider filings

Wall Street Analyst Weigh In

SGHT has been the topic of a number of recent analyst reports. Citigroup increased their price target on shares of Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Raymond James Financial set a $9.00 price target on Sight Sciences in a report on Monday. Piper Sandler set a $9.00 target price on Sight Sciences in a research report on Monday. Morgan Stanley upped their price objective on shares of Sight Sciences from $6.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Finally, Lake Street Capital lifted their target price on shares of Sight Sciences from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, October 21st. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Sight Sciences has an average rating of “Hold” and an average price target of $8.30.

Check Out Our Latest Stock Analysis on SGHT

Sight Sciences Company Profile

(Get Free Report)

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.

Featured Articles